The FDA approved Eli Lilly's Alzheimer's drug, expanding treatment options for the disease in the US. It will be sold under the brand name Kisunla. The drug targets plaques in the brain which are a hallmark of Alzheimer's disease. It has been shown to slow disease progression by 35% over 18 months compared to a placebo. The cost will range from $12,000 to $48,000. Medicare coverage is available for eligible patients. An estimated 7 million Americans currently have Alzheimer's disease, which is expected to rise to 13 million by 2050.
Category
🗞
NewsTranscript
00:00It's Benzinga and here's what's on the block.
00:02The FDA approved Eli Lilly's Alzheimer's drug expanding treatment options for the disease
00:08in the US.
00:09It will be sold under the brand name Casunla.
00:12The drug targets plaques in the brain which are a hallmark of Alzheimer's disease.
00:16It has also been shown to slow disease progression by 35% over 18 months compared to a placebo.
00:22The cost will range from $12,000 to $48,000.
00:26Medicare coverage is available for eligible patients.
00:29An estimated 7 million Americans currently have Alzheimer's disease which is expected
00:33to rise to 13 million by 2050.
00:35For all things money, visit Benzinga.com.